Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GF-CART01 in Relapsed or Refractory B-Cell Hematological Malignancies
NCT06703892Phase 1Recruiting
- Sponsor
- GenomeFrontier Therapeutics, Inc.
- Start
- Jun 2025
- Primary completion
- Mar 2027
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GF-CART01 in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), primary mediastinal large B-cell lymphoma (PMBCL) and 1 more, sponsored by GenomeFrontier Therapeutics, Inc. Primary endpoints: Maximum Tolerated Dose at 28 days and Safety and tolerability of GF-CART01 at 1 year. Started Jun 2025; status: recruiting.
02
Drugs
GF-CART01
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)primary mediastinal large B-cell lymphoma (PMBCL)high grade B-cell lymphoma (HGBCL)
Beyond the preview
Go deeper on NCT06703892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06703892.